Robert Wallace, MD
Family Medicine · St Petersburg, FLNPI 1821396151
Payments from drug & device makers
Across 694 payments — averaging $207.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$130K
- Viiv Healthcare Company$5K
- Gilead$3K
- Novo Nordisk$1K
- Theratechnologies Inc.$1K
- AstraZeneca$865
- plus $3K from 24 others
What the payments were for
- Consulting fees$1,4001%
- Speaking & faculty fees$108,08775%
- Travel & lodging$16,74612%
- Food & beverage$17,46712%
- Education$390%
- Entertainment$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 204 | $130,332 |
| Viiv Healthcare Company | 181 | $4,514 |
| Gilead | 96 | $2,778 |
| Novo Nordisk | 38 | $1,199 |
| Theratechnologies Inc. | 30 | $1,093 |
| AstraZeneca | 20 | $865 |
| Johnson & Johnson | 42 | $807 |
| Merck | 19 | $557 |
| Janssen Products, LP | 4 | $362 |
| Napo Pharmaceuticals Inc | 12 | $270 |
| EMD Serono, Inc. | 9 | $216 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $138 |
| Bioness Inc | 1 | $115 |
| Amarin Pharma, Inc. | 5 | $91 |
| Amgen | 3 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $74 |
| Evoke Pharma, Inc. | 3 | $46 |
| Hologic Sales And Service, LLC | 2 | $45 |
| Lilly USA, LLC | 2 | $39 |
| Exact Sciences | 2 | $39 |
| Verity Pharmaceuticals Inc. | 1 | $32 |
| Abbott | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$143,855 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 441 | $1,918,198 |
| DovatoDolutegravir Sodium/Lamivudine | 134 | $437,203 |
| DescovyEmtricitabine/Tenofov Alafenam | 150 | $337,742 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 70 | $275,205 |
| RukobiaFostemsavir Tromethamine | 29 | $255,502 |
| IngrezzaValbenazine Tosylate | 21 | $195,270 |
| JulucaDolutegravir/Rilpivirine | 50 | $181,202 |
| PrezcobixDarunavir/Cobicistat | 60 | $159,534 |
| TivicayDolutegravir Sodium | 55 | $158,065 |
| OzempicSemaglutide | 134 | $140,973 |
| MytesiCrofelemer | 48 | $123,082 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 22 | $94,364 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $78,483 |
| CreonLipase/Protease/Amylase | 23 | $51,935 |
| XifaxanRifaximin | 13 | $41,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $2,778 | $2,350,304613 claims |
| Viiv Healthcare CompanyDovato, Rukobia, Juluca, Tivicay | $4,514 | $1,031,971268 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $74 | $195,27021 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $807 | $177,95682 claims |
| Novo NordiskOzempic | $1,199 | $140,973134 claims |
| Napo Pharmaceuticals IncMytesi | $270 | $123,08248 claims |
| Janssen Products, LPSymtuza | $362 | $78,48318 claims |
| AbbVieCreon | $130,332 | $51,93523 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $138 | $41,79613 claims |
| Lilly USA, LLCMounjaro | $39 | $22,29914 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $865 | $21,67235 claims |
| PfizerEliquis | $15 | $12,83120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in St Petersburg
- Gigi LefebvreSt Petersburg$9.2M
- Roxana StoiciSt Petersburg$9.1M
- Linda MurraySt Petersburg$4.1M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.